What is 220? One Condition, Many Names

22q11.2 deletion syndrome occurs in an estimated 1/2000 births which makes it almost as common as Down syndrome.

So why haven't you heard of it?

Over the last few decades, this syndrome has had many different names, but all have the same underlying cause.

Opitz

DiGeorge Syndrome (DGS) G/BBB Syndrome

Velo-Cardio-Facial Syndrome (VCFS) Conotruncal Anomaly Face Syndrome (CTAF) Cayler Cardiofacial Syndrome

22q11.2 Deletion Syndrome

We now know that this genetic condition is caused by a small, missing or "deleted" piece of the 22nd chromosome, and that missing piece can affect every system in the human body.



75% of individuals with the 22q11.2 deletion have mild to life-threatening heart defects.



Differences in the palate, such as a cleft (hole in the roof of the mouth) or nasal speech are very common as are feeding and GI (gastrointestinal) problems.



Many individuals have immune system problems leading to trouble with infections or vaccines.





Low calcium levels and low growth-hormone levels may be present and are treatable.



1/3 of people with 22q have renal system differences such as a missing kidney.

Learning and behavioral differences, such as ADHD, anxiety, and other mental health issues are also diagnosed in some children and adults with the 22q11.2 deletion.



Inheritance

7% of 22q11.2 deletions are inherited from a parent with the deletion. Once the deletion is present there is a 50% recurrence risk.



The 22q11.2 deletion syndrome can cause many differences, ranging from mild to serious, making detection complex.

Early detection of 22q can lead to earlier interventions and better outcomes for affected individuals.



The mission of the International 22q11.2 Foundation is to improve the quality of life for individuals affected by the 22q11.2 syndromes through family and professional partnerships.

www.22q.org

Created with support from:

Inatera

Natera's Panorama[®] screen can provide parents with the first step toward the early detection of 22q11.2, so they can work with their healthcare providers to plan for any support that may be needed for the pregnancy, delivery, and care of their baby.

www.panoramatest.com

Sources

- McDonald-McGinn, D. M. et al. (2015) 22q11.2 deletion syndrome Nat. Rev. Dis. Primers doi:10.1038/nrdp.2015.71
- A review of the 22q11.2 Deletion Syndrome was published on November 19, 2015 in Nature. Donna M. McDonald-McGinn1, Kathleen E. Sullivan2, Bruno Marino3, Nicole Philip4, Ann Swillen5, Jacob A. S. Vorstman6, Elaine H. Zackai1, Beverly S. Emanuel7,
- Joris R. Vermeesch8, Bernice E. Morrow9, Peter J. Scambler10 and Anne S. Bassett. 22q11.2 deletion syndrome
- Article number: 15071; doi:10.1038/nrdp.2015.71 ; Published online 19 November 2015
- http://www.chop.edu/conditions-diseases/chromosome-22q112-deletion#.V1sT5uYrLoB
- https://ghr.nlm.nih.gov/condition/22q112-deletion-syndrome#statistics
- Wapner, et al. Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes. Am J Obstet Gynecol 2015; 212(3): 332.e1-9.

This test was developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratorydeveloped tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © 2016 Natera, Inc.